Insufficient scRNA-seq data for expression of OPRK1 at single-cell level.
Insufficient scRNA-seq data for expression of OPRK1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| prostate | 68% | 132.48 | 166 / 245 | 79% | 6.98 | 397 / 502 |
| brain | 89% | 342.08 | 2349 / 2642 | 26% | 0.75 | 185 / 705 |
| adrenal gland | 2% | 0.51 | 4 / 258 | 38% | 2.17 | 87 / 230 |
| adipose | 29% | 19.68 | 345 / 1204 | 0% | 0 | 0 / 0 |
| lung | 4% | 1.53 | 22 / 578 | 22% | 1.02 | 249 / 1155 |
| heart | 22% | 14.27 | 189 / 861 | 0% | 0 | 0 / 0 |
| ovary | 0% | 0 | 0 / 180 | 17% | 0.45 | 73 / 430 |
| bladder | 10% | 3.57 | 2 / 21 | 7% | 0.23 | 33 / 504 |
| intestine | 13% | 6.15 | 130 / 966 | 2% | 0.10 | 13 / 527 |
| breast | 7% | 3.46 | 31 / 459 | 8% | 0.45 | 94 / 1118 |
| uterus | 1% | 0.42 | 1 / 170 | 14% | 1.13 | 66 / 459 |
| thymus | 9% | 4.44 | 61 / 653 | 5% | 0.19 | 33 / 605 |
| esophagus | 0% | 0.74 | 7 / 1445 | 10% | 0.45 | 19 / 183 |
| blood vessel | 10% | 5.46 | 136 / 1335 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 7% | 0.11 | 3 / 45 |
| muscle | 6% | 3.50 | 45 / 803 | 0% | 0 | 0 / 0 |
| stomach | 1% | 0.47 | 5 / 359 | 2% | 0.13 | 7 / 286 |
| pancreas | 0% | 0 | 0 / 328 | 3% | 0.14 | 6 / 178 |
| skin | 1% | 0.37 | 13 / 1809 | 1% | 0.06 | 6 / 472 |
| liver | 1% | 0.40 | 2 / 226 | 1% | 0.26 | 3 / 406 |
| kidney | 0% | 0 | 0 / 89 | 1% | 0.04 | 12 / 901 |
| eye | 0% | 0 | 0 / 0 | 1% | 0.01 | 1 / 80 |
| spleen | 1% | 0.27 | 2 / 241 | 0% | 0 | 0 / 0 |
| peripheral blood | 0% | 0.23 | 2 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0019233 | Biological process | sensory perception of pain |
| GO_0044849 | Biological process | estrous cycle |
| GO_1901381 | Biological process | positive regulation of potassium ion transmembrane transport |
| GO_0033603 | Biological process | positive regulation of dopamine secretion |
| GO_0071333 | Biological process | cellular response to glucose stimulus |
| GO_0007218 | Biological process | neuropeptide signaling pathway |
| GO_0007200 | Biological process | phospholipase C-activating G protein-coupled receptor signaling pathway |
| GO_0043627 | Biological process | response to estrogen |
| GO_1990708 | Biological process | conditioned place preference |
| GO_0031635 | Biological process | adenylate cyclase-inhibiting opioid receptor signaling pathway |
| GO_0051607 | Biological process | defense response to virus |
| GO_1903937 | Biological process | response to acrylamide |
| GO_0032868 | Biological process | response to insulin |
| GO_0007600 | Biological process | sensory perception |
| GO_0033685 | Biological process | negative regulation of luteinizing hormone secretion |
| GO_0046877 | Biological process | regulation of saliva secretion |
| GO_1904000 | Biological process | positive regulation of eating behavior |
| GO_0045471 | Biological process | response to ethanol |
| GO_1900745 | Biological process | positive regulation of p38MAPK cascade |
| GO_0006955 | Biological process | immune response |
| GO_0042711 | Biological process | maternal behavior |
| GO_0007193 | Biological process | adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway |
| GO_0007268 | Biological process | chemical synaptic transmission |
| GO_0042755 | Biological process | eating behavior |
| GO_0007626 | Biological process | locomotory behavior |
| GO_0035094 | Biological process | response to nicotine |
| GO_0071222 | Biological process | cellular response to lipopolysaccharide |
| GO_0048148 | Biological process | behavioral response to cocaine |
| GO_0050951 | Biological process | sensory perception of temperature stimulus |
| GO_0038003 | Biological process | G protein-coupled opioid receptor signaling pathway |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0016020 | Cellular component | membrane |
| GO_0005739 | Cellular component | mitochondrion |
| GO_0043204 | Cellular component | perikaryon |
| GO_0030672 | Cellular component | synaptic vesicle membrane |
| GO_0043679 | Cellular component | axon terminus |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0043005 | Cellular component | neuron projection |
| GO_0042734 | Cellular component | presynaptic membrane |
| GO_0030425 | Cellular component | dendrite |
| GO_0030315 | Cellular component | T-tubule |
| GO_0005829 | Cellular component | cytosol |
| GO_0016529 | Cellular component | sarcoplasmic reticulum |
| GO_0045211 | Cellular component | postsynaptic membrane |
| GO_0004985 | Molecular function | G protein-coupled opioid receptor activity |
| GO_0038048 | Molecular function | dynorphin receptor activity |
| GO_0042923 | Molecular function | neuropeptide binding |
| GO_0033612 | Molecular function | receptor serine/threonine kinase binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | OPRK1 |
| Protein name | Opioid receptor kappa 1 Kappa-type opioid receptor (K-OR-1) (KOR-1) Kappa-type opioid receptor |
| Synonyms | OPRK KOP KOR1 KOR |
| Description | FUNCTION: G-protein coupled opioid receptor that functions as a receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as a receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain. Plays a role in mediating reduced physical activity upon treatment with synthetic opioids. Plays a role in the regulation of salivation in response to synthetic opioids. May play a role in arousal and regulation of autonomic and neuroendocrine functions. . FUNCTION: G-protein coupled opioid receptor that functions as a receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as a receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain. Plays a role in mediating reduced physical activity upon treatment with synthetic opioids. Plays a role in the regulation of salivation in response to synthetic opioids. May play a role in arousal and regulation of autonomic and neuroendocrine functions. . FUNCTION: G-protein coupled opioid receptor that functions as a receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as a receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain. Plays a role in mediating reduced physical activity upon treatment with synthetic opioids. Plays a role in the regulation of salivation in response to synthetic opioids. May play a role in arousal and regulation of autonomic and neuroendocrine functions. . |
| Accessions | E5RJI5 P41145 A0A6H0WCN5 ENST00000520287.5 [P41145-1] A0A6H0WB68 ENST00000524278.5 [P41145-2] ENST00000265572.8 [P41145-1] ENST00000673285.2 A0A5F9ZI09 ENST00000522508.1 |